Ivosidenib with azacitidine for previously untreated acute myeloid leukaemia with an IDH1 mutation

Ivosidenib is in development with azacitidine for the treatment of patients with newly diagnosed acute myeloid leukaemia (AML) who have an isocitrate dehydrogenase 1 (IDH1) mutation and are ineligible for intensive induction chemotherapy. AML is a rare form of blood cancer that affects the white blood cells resulting in frequent infections for patients. AML also affects red blood cells resulting in other symptoms such as bleeding and breathlessness. AML is an acute cancer which means it progresses quickly and aggressively, needing immediate treatment. IDH1 mutations make the cells act in an abnormal way and multiply in an uncontrolled accelerated rate. There are currently no recommended targeted therapies for IDH1 mutations and prognosis is poor in this population of patients.